Transient increment of HTLV-2 proviral load in HIV-1-co-infected patients during treatment intensification with raltegravir.
BACKGROUND
Numerous studies have analyzed the effects of raltegravir intensification on HIV-1 viral replication in infected individuals receiving suppressive combined antiretroviral treatment (cART). Nevertheless, there are only two studies on the effect of raltegravir in HTLV-1 infection, and none in HTLV-2.


OBJECTIVE
To study the effect of raltegravir on HTLV-2 infection in HIV-1-co-infected individuals.


METHODS
This retrospective longitudinal study included four HTLV-2-HIV-1-co-infected individuals who received raltegravir-based cART during 48 weeks and 11 HTLV-2-HIV-1-co-infected individuals under cART without raltegravir during 48 weeks. HTLV-2 proviral load, CD4 and CD8 count and frequency were analyzed.


RESULTS
HTLV-2 proviral load significantly increased at week 24 compared to baseline among all the patients who received raltegravir (p=0.003), while no significant increases were found in the control group. No significant variation in either CD8 or CD4 counts was found during the follow up in both groups.


CONCLUSIONS
Raltegravir induced a transient increment on total HTLV-2 DNA proviral load in HTLV-2/HIV-1-coinfected individuals on suppressive cART after 24 weeks.
Laboratory of Immunovirology, Department of Infectious Diseases, Universitary Hospital Ramón y Cajal, 28034 Madrid, Spain.
María
M
Abad-Fernández
IrsiCaixa-HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, 08916 Barcelona, Spain.
Cecilia
C
Cabrera
IrsiCaixa-HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, 08916 Barcelona, Spain.
Elisabet
E
García
Laboratory of Immunovirology, Department of Infectious Diseases, Universitary Hospital Ramón y Cajal, 28034 Madrid, Spain. Electronic address: avallejot@gmail.com.
Alejandro
A
Vallejo
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D060085:Coinfection; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D015491:HTLV-II Infections / Q000150:complications / Q000453:epidemiology / Q000821:virology*; D015367:Human T-lymphotropic virus 2 / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011760:Pyrrolidinones / Q000494:pharmacology* / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D019562:Viral Load / Q000187:drug effects*
D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium
HIV-1 coinfection; HTLV-2 proviral load; Raltegravir